VeonGen Presents Clinical Progress of VG801 at ARVO 2026

VeonGen Therapeutics has announced promising clinical progress for its VG801 gene therapy targeting Stargardt disease. Preliminary data from the ongoing Phase 1/2 trial reveals consistent improvements in visual acuity, with these gains maintained over six and twelve months. Importantly, VG801 has demonstrated a favorable safety profile, with no severe side effects reported.

The trial's progress includes support from key regulatory programs such as the FDA’s RDEA and RMAT designation, indicating a potential fast track for approval. VeonGen is set to present these findings at the ARVO 2026 meeting, highlighting the therapy’s significance in retinal treatment. Additionally, VG801 has secured essential regulatory clearances required for continued clinical development.